Efficacy analysis of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma
Abstract To investigate the effectiveness of TACE in combination with anlotinib and sintilimab in the treatment of unresectable hepatocellular carcinoma. A total of 210 patients with primary unresectable hepatocellular carcinoma (PAC) in our hospital from January 2020 to December 2023 were selected...
שמור ב:
| Principais autores: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2025-11-01
|
| סדרה: | Scientific Reports |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1038/s41598-025-25728-4 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|